China's Abbisko Cayman near 3-year peak on share buyback plan
** Abbisko Cayman 2256.HK jumps 9.5% to HK$6.92, highest since June 2022 ** Stock set for biggest one-day pct rise since February 20 ** Chinese oncology therapies developer says it will buy back shares on-market for up to HK$200 mln ($25.73 mln), reflecting management's confidence in firm's operational growth outlook, financial position ** Stock up 48.7% YTD ($1 = HK$7.7743) (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly